Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8770199 | 0.84 | PTGS2 (0.53) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6904881 | 0.84 | PTGS2 (0.68) | PTGS2PTGS1ALOX5 | |
| SCHEMBL11133788 | 0.80 | PTGS2 (0.39) | PTGS2PTGS1 | |
| SCHEMBL1424128 | 0.75 | LRRK2 (0.46) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6050700 | 0.74 | PTGS2 (0.55) | PTGS2PTGS1ALOX5 | |
| SCHEMBL9395238 | 0.74 | PTGS2 (0.65) | PTGS2PTGS1ALOX5 | |
| SCHEMBL215130 | 0.73 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL9393666 | 0.72 | PTGS2 (0.66) | PTGS2PTGS1ALOX5 | |
| SCHEMBL8650160 | 0.72 | PTGS2 (0.69) | PTGS2 | |
| SCHEMBL9797523 | 0.72 | HSD11B1 (0.57) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1911740-A1 | POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2008-04-16 | — | — | EP | claimed |
| US-20070161607-A1 | Potassium channel modulators | SANIONA A/S (DK) | 2007-07-12 | — | — | US | claimed |
| US-20050009816-A1 | Potassium channel modulators | SANIONA A/S (DK) | 2005-01-13 | — | — | US | claimed |
| EP-1465863-A1 | POTASSIUM CHANNEL MODULATORS | Poseidon Pharmaceuticals A/S (DK) | 2004-10-13 | — | — | EP | claimed |
| WO-2003059873-A1 | POTASSIUM CHANNEL MODULATORS | POSEIDON PHARMACEUTICALS A/S (DK) | 2003-07-24 | — | — | WO | claimed |
| US-7429618-B2 | Potassium channel modulators | NEUROSEARCH A/S (DK) | 2008-09-30 | — | — | US | disclosed |
| EP-1911740-A1 | POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2008-04-16 | — | — | EP | disclosed |
| US-20070161607-A1 | Potassium channel modulators | SANIONA A/S (DK) | 2007-07-12 | — | — | US | disclosed |
| US-7208527-B2 | Potassium channel modulators | POSEIDON PHARMACEUTICALS A/S (DK) | 2007-04-24 | — | — | US | disclosed |
| US-20050009816-A1 | Potassium channel modulators | SANIONA A/S (DK) | 2005-01-13 | — | — | US | disclosed |
| EP-1465863-A1 | POTASSIUM CHANNEL MODULATORS | Poseidon Pharmaceuticals A/S (DK) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003059873-A1 | POTASSIUM CHANNEL MODULATORS | POSEIDON PHARMACEUTICALS A/S (DK) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009816-A1 | Potassium channel modulators | KCNC1, KCNQ1, KCNA1 | PTGS2 2447/4885PTGS1 1947/4885ALOX5 4034/4885 |
| US-20070161607-A1 | Potassium channel modulators | KCNC1, KCNQ1, KCNA1 | PTGS2 2447/4885PTGS1 1947/4885ALOX5 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.